I
266.30
9.45 (3.68%)
| Previous Close | 256.85 |
| Open | 258.00 |
| Volume | 416,999 |
| Avg. Volume (3M) | 545,139 |
| Market Cap | 18,679,560,192 |
| Price / Earnings (TTM) | 45.44 |
| Price / Earnings (Forward) | 66.23 |
| Price / Sales | 9.89 |
| Price / Book | 16.12 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | 21.22% |
| Operating Margin (TTM) | 16.20% |
| Diluted EPS (TTM) | 5.88 |
| Quarterly Revenue Growth (YOY) | 25.70% |
| Quarterly Earnings Growth (YOY) | 49.30% |
| Total Debt/Equity (MRQ) | 128.91% |
| Current Ratio (MRQ) | 3.68 |
| Operating Cash Flow (TTM) | 327.80 M |
| Levered Free Cash Flow (TTM) | 106.08 M |
| Return on Assets (TTM) | 7.57% |
| Return on Equity (TTM) | 48.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Insulet Corporation | Bullish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.33% |
| % Held by Institutions | 103.25% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 330.00 (JP Morgan, 23.92%) | Buy |
| Median | 304.50 (14.35%) | |
| Low | 234.00 (Barclays, -12.13%) | Hold |
| Average | 295.40 (10.93%) | |
| Total | 9 Buy, 1 Hold | |
| Avg. Price @ Call | 264.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 03 Jan 2025 | 324.00 (21.67%) | Buy | 266.30 |
| JP Morgan | 12 Dec 2024 | 330.00 (23.92%) | Buy | 271.73 |
| Citigroup | 11 Dec 2024 | 310.00 (16.41%) | Buy | 273.47 |
| Wells Fargo | 11 Dec 2024 | 305.00 (14.53%) | Buy | 273.47 |
| Canaccord Genuity | 09 Dec 2024 | 304.00 (14.16%) | Buy | 265.12 |
| Barclays | 11 Nov 2024 | 234.00 (-12.13%) | Hold | 275.70 |
| Morgan Stanley | 11 Nov 2024 | 317.00 (19.04%) | Buy | 275.70 |
| BTIG | 08 Nov 2024 | 270.00 (1.39%) | Buy | 268.00 |
| 14 Oct 2024 | 260.00 (-2.37%) | Buy | 232.51 | |
| Bernstein | 06 Nov 2024 | 300.00 (12.65%) | Buy | 239.30 |
| Raymond James | 14 Oct 2024 | 260.00 (-2.37%) | Buy | 232.51 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Dec 2024 | Announcement | Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court |
| 20 Nov 2024 | Announcement | Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S. |
| 15 Nov 2024 | Announcement | Insulet to Present at Upcoming Investor Conferences |
| 07 Nov 2024 | Announcement | Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency¹) |
| 01 Nov 2024 | Announcement | Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November |
| 29 Oct 2024 | Announcement | Omnipod® 5 App for iPhone® Now Fully Available in the United States |
| 10 Oct 2024 | Announcement | National Campaign Launches to Combat Diabetes Stigma Using Comedy |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |